These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16105079)

  • 21. Increased serum asymmetric dimethylarginine level is an independent predictor of contrast-induced nephropathy.
    Kalayci B; Kalayci S; Çolak A
    Turk Kardiyol Dern Ars; 2014 Jan; 42(1):117. PubMed ID: 25826828
    [No Abstract]   [Full Text] [Related]  

  • 22. N-acetylcysteine and contrast-induced nephropathy.
    Wolak A; Cafri C; Zahger D
    N Engl J Med; 2006 Oct; 355(14):1498; author reply 1499-500. PubMed ID: 17024739
    [No Abstract]   [Full Text] [Related]  

  • 23. Editorial: contrast-induced acute kidney injury: shifting from elective to urgent coronary intervention.
    McCullough PA
    J Interv Cardiol; 2010 Oct; 23(5):467-9. PubMed ID: 20731756
    [No Abstract]   [Full Text] [Related]  

  • 24. Early ambulation strategies with contrast management.
    Lim MJ
    J Invasive Cardiol; 2005 Jan; 17(1):42-3; quiz 44. PubMed ID: 15640540
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk markers for contrast-induced nephropathy.
    Toprak O
    Am J Med Sci; 2007 Oct; 334(4):283-90. PubMed ID: 18030185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrast-induced nephropathy remains a serious complication of PCI.
    Mehran R
    J Interv Cardiol; 2007 Jun; 20(3):236-40. PubMed ID: 17524117
    [No Abstract]   [Full Text] [Related]  

  • 27. Percutaneous coronary intervention complications and guide catheter size: bigger is not better.
    Grossman PM; Gurm HS; McNamara R; Lalonde T; Changezi H; Share D; Smith DE; Chetcuti SJ; Moscucci M;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):636-44. PubMed ID: 19628187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast-induced nephropathy morbidity and mortality following percutaneous coronary intervention.
    Brown JR; Solomon RJ
    Am J Cardiol; 2009 Dec; 104(12):1763. PubMed ID: 19962490
    [No Abstract]   [Full Text] [Related]  

  • 29. N-acetylcysteine and contrast-induced nephropathy.
    Balderramo DC
    N Engl J Med; 2006 Oct; 355(14):1498-9; author reply 1499-500. PubMed ID: 17024740
    [No Abstract]   [Full Text] [Related]  

  • 30. Contrast-induced monoplegia following coronary angioplasty with iopromide.
    Aykan A; Zehir R; Karabay CY; Kocabay G
    Kardiol Pol; 2012; 70(5):499-500. PubMed ID: 22623245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.
    Dangas G; Iakovou I; Nikolsky E; Aymong ED; Mintz GS; Kipshidze NN; Lansky AJ; Moussa I; Stone GW; Moses JW; Leon MB; Mehran R
    Am J Cardiol; 2005 Jan; 95(1):13-9. PubMed ID: 15619387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral versus intravenous hydration and renal function in diabetic patients undergoing percutaneous coronary interventions.
    Wróbel W; Sinkiewicz W; Gordon M; Woźniak-Wiśniewska A
    Kardiol Pol; 2010 Sep; 68(9):1015-20. PubMed ID: 20859892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic strategy for prevention of contrast-induced nephropathy].
    Suzuki H
    Nihon Rinsho; 2011 Sep; 69 Suppl 7():220-5. PubMed ID: 22518995
    [No Abstract]   [Full Text] [Related]  

  • 34. Sodium bicarbonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy.
    Bouzas-Mosquera A; Recio-Mayoral A
    Am Heart J; 2008 Apr; 155(4):e31. PubMed ID: 18371455
    [No Abstract]   [Full Text] [Related]  

  • 35. N-acetylcysteine and contrast-induced nephropathy.
    Ritz E
    N Engl J Med; 2006 Oct; 355(14):1499; author reply 1499-500. PubMed ID: 17024738
    [No Abstract]   [Full Text] [Related]  

  • 36. The value of hydration and acetylcysteine in the prevention of contrast-induced nephropathy: a potentially catastrophic complication of the percutaneous coronary interventions.
    Iyisoy A; Celik T; Yuksel UC; Bugan B; Isik E
    Int J Cardiol; 2009 May; 134(3):431-3; author reply 434. PubMed ID: 18501445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ameliorating contrast-induced nephropathy.
    Ramanathan K; Webb J
    J Invasive Cardiol; 2001 Nov; 13(11):741. PubMed ID: 11689717
    [No Abstract]   [Full Text] [Related]  

  • 38. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
    Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
    Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency.
    Yoshida S; Kamihata H; Nakamura S; Senoo T; Manabe K; Motohiro M; Sugiura T; Iwasaka T
    J Cardiol; 2009 Oct; 54(2):192-8. PubMed ID: 19782255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.